Universal Beteiligungs und Servicegesellschaft mbH Has $12.56 Million Stock Position in United Therapeutics Corporation $UTHR

Universal Beteiligungs und Servicegesellschaft mbH decreased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 6.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,694 shares of the biotechnology company’s stock after selling 2,996 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in United Therapeutics were worth $12,555,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Chung Wu Investment Group LLC bought a new stake in United Therapeutics during the 2nd quarter valued at $29,000. SVB Wealth LLC bought a new stake in shares of United Therapeutics during the first quarter worth about $32,000. Geneos Wealth Management Inc. lifted its position in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares in the last quarter. Brooklyn Investment Group boosted its stake in United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 98 shares during the last quarter. Finally, WPG Advisers LLC bought a new stake in United Therapeutics during the 1st quarter worth approximately $60,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $476.54 on Thursday. The firm has a market cap of $20.52 billion, a price-to-earnings ratio of 18.06, a P/E/G ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $485.32. The firm’s 50-day simple moving average is $436.99 and its two-hundred day simple moving average is $353.41.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same quarter last year, the business posted $6.39 EPS. United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. Analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 4,000 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $467.55, for a total value of $1,870,200.00. Following the sale, the chief executive officer directly owned 130 shares in the company, valued at approximately $60,781.50. The trade was a 96.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $464.76, for a total transaction of $5,112,360.00. Following the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at $17,094,337.56. This represents a 23.02% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 511,935 shares of company stock worth $221,082,497. Insiders own 10.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on UTHR. HC Wainwright lifted their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Oppenheimer upped their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Weiss Ratings reissued a “buy (b-)” rating on shares of United Therapeutics in a research report on Thursday, November 13th. Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research report on Wednesday. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $505.00.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.